KalVista Pharmaceuticals, Inc. Common Stock (KALV)

Price$19.56

Favorite Metrics

Price vs S&P 500 (26W)77.56%

Price vs S&P 500 (4W)28.85%

Market Capitalization$1.07B

All Metrics

Book Value / Share (Quarterly)$0.34

P/TBV (Annual)1.74x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-2.44

Price vs S&P 500 (YTD)26.52%

Net Profit Margin (TTM)-119.17%

EPS (TTM)$-1.15

10-Day Avg Trading Volume0.96M

EPS Excl Extra (TTM)$-1.15

Revenue Growth (5Y)31.06%

EPS (Annual)$-2.03

ROI (Annual)-61.30%

Gross Margin (Annual)93.72%

Net Profit Margin (5Y Avg)-402.03%

Cash / Share (Quarterly)$5.90

ROA (Last FY)-32.66%

EBITD / Share (TTM)$-1.01

ROE (5Y Avg)-43.24%

Operating Margin (TTM)-123.46%

Cash Flow / Share (Annual)$-1.64

P/B Ratio62.86x

P/B Ratio (Quarterly)36.20x

Net Income / Employee (Annual)$-0

EV / Revenue (TTM)20.60x

Net Interest Coverage (TTM)-43.96x

ROA (TTM)-20.27%

EPS Incl Extra (Annual)$-2.03

Current Ratio (Annual)5.58x

Quick Ratio (Quarterly)5.43x

3-Month Avg Trading Volume1.06M

52-Week Price Return74.56%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$4.07

P/S Ratio (Annual)21.77x

Asset Turnover (Annual)0.15x

52-Week High$21.30

Operating Margin (5Y Avg)-488.97%

EPS Excl Extra (Annual)$-2.03

CapEx CAGR (5Y)88.34%

Tangible BV CAGR (5Y)42.66%

26-Week Price Return81.55%

Quick Ratio (Annual)5.43x

13-Week Price Return27.27%

Total Debt / Equity (Annual)1.11x

Current Ratio (Quarterly)5.58x

Enterprise Value$1,040.146

Revenue / Share Growth (5Y)4.97%

Asset Turnover (TTM)0.17x

Book Value / Share Growth (5Y)-16.43%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-225.27%

Cash / Share (Annual)$5.90

3-Month Return Std Dev60.33%

Net Income / Employee (TTM)$-0

ROE (Last FY)-61.30%

Net Interest Coverage (Annual)0.34x

EPS Basic Excl Extra (Annual)$-2.03

Total Debt / Equity (Quarterly)16.00x

EPS Incl Extra (TTM)$-1.15

ROI (TTM)-76.42%

P/S Ratio (TTM)21.16x

Pretax Margin (5Y Avg)-402.48%

Revenue / Share (Annual)$0.91

Tangible BV / Share (Annual)$4.71

Price vs S&P 500 (52W)44.73%

Year-to-Date Return29.16%

5-Day Price Return4.56%

EPS Normalized (Annual)$-2.03

ROA (5Y Avg)-38.91%

Net Profit Margin (Annual)-223.16%

Month-to-Date Return3.63%

Cash Flow / Share (TTM)$-3.11

EBITD / Share (Annual)$-1.99

Operating Margin (Annual)-228.28%

LT Debt / Equity (Annual)1.11x

ROI (5Y Avg)-43.24%

LT Debt / Equity (Quarterly)15.81x

EPS Basic Excl Extra (TTM)$-1.15

P/TBV (Quarterly)2.01x

P/B Ratio (Annual)7.18x

Pretax Margin (TTM)-123.67%

Book Value / Share (Annual)$1.92

Price vs S&P 500 (13W)26.59%

Beta-0.35x

P/FCF (Annual)117.03x

Revenue / Share (TTM)$0.92

ROE (TTM)-237.53%

52-Week Low$9.83

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.33

Industry Peers — Pharmaceuticals(309)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
KALVKalVista Pharmaceuticals, Inc. Common Stock	21.16x	—	—	—	$19.56
LLYEli Lilly & Co.	13.08x	44.70%	83.04%	27.59%	$903.99
JNJJohnson & Johnson	5.94x	7.87%	67.95%	14.90%	$234.54
ABBVABBVIE INC.	6.04x	8.57%	71.62%	-2.88%	$208.99
MRKMerck & Co., Inc.	4.41x	1.31%	78.55%	21.23%	$115.46
AZNAstraZeneca PLC	5.28x	8.63%	81.31%	21.88%	$200.47
NVSNovartis AG	4.98x	8.91%	75.82%	15.26%	$149.73
NVONovo-Nordisk A/S	3.62x	6.43%	80.98%	20.66%	$40.93
ABTAbbott Laboratories	3.66x	6.59%	56.50%	8.20%	$95.47
PFEPfizer Inc.	2.47x	-1.64%	75.81%	-3.51%	$27.22
BMYBristol-Myers Squibb Co.	2.47x	-0.22%	72.63%	—	$58.96

About

KalVista Pharmaceuticals develops oral small-molecule therapies targeting the kallikrein-kinin system for rare genetic and acquired disorders with significant unmet medical needs. The company's commercial product, EKTERLY (sebetralstat), is an FDA-approved plasma kallikrein inhibitor for acute hereditary angioedema (HAE) attacks in patients aged 12 and older. Leveraging its novel oral drug discovery platform, KalVista is positioned to address multiple orphan indications in disease areas with limited treatment options.